Meet the 2025 ISPE Facility of the Year Awards (FOYA) Category Winner for Operations, Project Execution: Johnson & Johnson Innovative Medicine – Ireland
ISPE
Johnson & Johnson Innovative Medicine, part of the Johnson & Johnson family of companies, develops innovative and integrated products and medicines to restore and extend the quality of life for patients globally. The expansion of Johnson & Johnson’s BioCork facility in Ringaskiddy, Cork, Ireland increased the existing biomanufacturing capacity at the plant while also creating employment for 180 people in the local community. Expansion of the existing manufacturing facility incorporates additional capacity in large-scale fed-batch technology which will help guarantee efficient and sustainable delivery of biologic medicines in the areas of immunology and oncology.
This project is recognized as the 2025 FOYA category winner in Operations – Project Execution due to the following reasons:
Safety adherence with a low recordable incident rate (TRIR) and drug-associated risk tool (DART) performance
Complexity factor with the expansion conducted while the existing plant continued to operate
Integrated teams with Johnson & Johnson working closely with their partners
Innovation and process intelligence with the use of new technology and operations strategies to improve operational and project performance
Social impact with a focus on sustainability and its impact on the local community, as part of Johnson & Johnson’s credo
The project had five clear objectives which were accomplished:
Committed to getting everyone home safely every day, the project had 2,600,000 safe man hours
In compliance with environmental, health, and safety and quality standards, the team managed over 1,100 safety audits and successful regulatory inspections
No disruption to current production with no unplanned manufacturing downtime
A fully integrated approach with the current manufacturing site; 80 batches were successfully manufactured and released during the project’s timespan
Completion within budget and on schedule: the project was completed under budget and 11 months ahead of schedule
This large capital expansion had a large complexity factor as the team constructed this facility within a live plant, which entailed navigating complex challenges to achieve seamless integration and no manufacturing disruption. This required innovative risk management strategies to proactively identify and mitigate potential hazards to ongoing operations. A clear team structure was vital for effective communication and coordination among stakeholders while interfacing with existing site activities.
The project complexity necessitated exceptional interdependent collaboration, leading them to implement innovative strategies for the safe and efficient delivery of quality products and services. At its peak, the project had over 850 personnel on site supporting the expansion. A multifunctional team oversaw all phases from concept to operations. Project interface leads played a crucial role in coordinating construction activities with manufacturing operations while maintaining safety and compliance.
Johnson & Johnson established a safety culture that encouraged a proactive reporting of safety observations based on a “see something, say something, do something” philosophy. This commitment to safety as a core value in the delivery of this project delivered an impressive safety performance with a TRIR of 0.075, and DART of 0.075.
From a social impact point of view, the project achieved a LEED Silver Certification for the manufacturing expansion areas. The project will save ~3000 m3 of water each year and over three tons of disposable materials.
In terms of innovation, the teams used the following strategies to improve project performance via use of drone and virtuality reality for collaborative decision making. The engineering and construction process used a digitally enabled strategy from commissioning through operational readiness where all documentations with digitally and totally paperless.
Based on these innovative ways of working and implementing this project in a safe and sustainable manner, Johnson & Johnson Innovative Medicine is recognized as the 2025 ISPE FOYA category winner for Operations – Project Execution.
Supply Partners and Key Participants
Manufacturer/Owner Name: Johnson & Johnson Innovative Medicines Ireland
Engineer/Architect: PM Group, Cork Office
Construction Manager: PM Group, Cork Office
Commissioning: PM Group, Cork Office
CSA: John Sisk & Sons, Cork Office
Piping Subcontractor: Radley Engineering Limited
Electrical Subcontractor: STS
Automation and Control Supplier: Cognizant, Cork Office
About the Operations Category
Winners in this category exemplify the application of novel tools and approaches to delivering projects that improved efficiencies, overcame unusual challenges, promoted effectiveness, and organized stakeholders and project team participants in ways that led to successful outcomes such as efficiency, delivery, quality, product yield, consistency, and cost of goods. Projects demonstrate a culture of continuous improvement behaviors which yielded superior results. Additionally, these principles, systems and tools ensure business continuity through a stable supply environment, health and safety, and customer satisfaction from existing or new facilities, processes, and manufacturing operations.>
The 2026 FOYA Banquet and Awards Celebration will occur on Sunday, 18 October, during the 2026 ISPE Annual Meeting & Expo in Washington D.C., USA, 18-21 October. All are welcome to register to join the prestigious black-tie event. The event will include speeches from award recipients, keynote sessions from industry leaders, and abundant opportunities to connect with manufacturing and engineering experts.
ISPE’s Facility of the Year Awards (FOYA) is a leading global program recognizing innovation in pharmaceutical and biotechnology manufacturing. It highlights achievements in facility design, construction, and operation, celebrating the commitment of individuals worldwide to improve patient health. Award categories include Innovation, Operations, Supply Chain, Pharma 4.0™, and Social Impact, showcasing excellence in the industry.
The submission deadline is Monday, 7 December 2026.
Established in 2005, the FOYA program recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches.
ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.
How do you validate cleaning processes for ADCs, monoclonal antibodies (mAbs), and highly potent active pharmaceutical ingredients (HPAPIs)? What role do degradation studies, cleaning-agent selection, and analytical testing play in reducing validation risk and supporting regulatory expectations?
Pharmaceutical manufacturing depends on precision, rigor, and compliance. But technical excellence alone does not keep operations moving. Engineers, quality professionals, production teams, scientists, and regulatory personnel must continually exchange technical information, make decisions, and align around shared priorities.
A biologic drug product compounding step often transfers seamlessly on paper. The formulation is unchanged, the order of addition is the same, and the target concentration remains identical. The batch record at the receiving site calls for the qualified mixing speed and mixing time, and that is what the operator follows. Everything appears to match.